Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17773337 | 0.98 | MEN1 (0.38) | MEN1CYP2C19KMT2ACYP1A2CYP3A4 | |
| SCHEMBL20230782 | 0.86 | HSD11B1 (0.36) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL20230797 | 0.83 | HTT (0.36) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL20230799 | 0.82 | — | — | |
| SCHEMBL20230789 | 0.82 | CYP1A2 (0.41) | CYP2C19CYP1A2ALDH1A1MAPTHPGD | |
| SCHEMBL20230793 | 0.82 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL20230798 | 0.81 | — | — | |
| SCHEMBL17426252 | 0.79 | ELANE (0.34) | MEN1CYP2C19KMT2AELANEALDH1A1 | |
| SCHEMBL17250748 | 0.78 | ELANE (0.36) | MEN1CYP2C19KMT2AELANEALDH1A1 | |
| SCHEMBL19026921 | 0.78 | L3MBTL1 (0.34) | MEN1CYP2C19KMT2AELANEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK17, CDK1 | MEN1 1347/4885CYP2C19 1274/4885KMT2A 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.